Published in Gene Therapy Weekly, April 6th, 1998
AAV vectors are very useful vehicles for gene transfer. Like other viral vectors, however, initial transgene expression diminishes over time and readministration of the vector is limited because of the host's initial immune response to viral components of the vector.
William C. Manning and colleagues from Chiron Corporation, California, demonstrated that the use of immunosuppressive antibodies during initial vector administration would allow transgene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.